A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s body’s defences to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when immunised 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from day one
- Protection achievable with two-week gap before premature birth
- Vaccination in the third trimester still offers significant protection for infants
Compelling evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study carried out throughout England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that half-year window, providing strong and reliable information of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation gives healthcare professionals and parents-to-be with trust in the vaccine’s established performance across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology captured actual clinical results rather than laboratory-based settings, providing practical evidence of how the vaccine functions when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it extremely challenging for affected infants to breathe and feed effectively. Parents commonly see their babies fighting for breath, their chests heaving as they attempt to draw sufficient oxygen into their damaged lungs. Whilst the majority of babies get better with clinical support, a small but significant group succumb from RSV complications each year, making vaccination as prevention a critical public health objective for safeguarding the youngest and most at-risk individuals in the population.
- RSV triggers lung inflammation, causing serious respiratory problems in babies
- Half of all infants catch the infection in their first few months of life
- Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
- More than 20,000 UK infants need serious hospital treatment for RSV each year
- Few babies succumb to RSV complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These geographical variations demonstrate variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts deploying multiple messaging strategies to connect with expectant mothers
- Regional disparities in immunisation take-up throughout England require targeted improvement
- Local healthcare systems adapting programmes to meet community needs and circumstances
Real-world impact and parent viewpoints
The vaccine’s remarkable effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% drop in admissions means thousands of infants protected against critical disease. Parents no more face the distressing scenario of watching their newborns gasping for air or labour to feed, symptoms that mark serious RSV disease. The vaccine has substantially transformed the terrain of neonatal breathing health, providing expectant mothers a active means to protect their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab underscores the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to expectant mothers navigating their third trimester, converting what was once an predictable seasonal threat into a controllable health concern.